Beam Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Good morning, and thank you for joining the fifth annual Guggenheim Genomic Medicines and Rare Disease Conference. I am Debjit and my pleasure to have John Evans, the Chief Executive Officer of Beam Therapeutics.
Great to be here.
Questions & Answers
Awesome, so let's maybe help people understand base editing and more because I think a lot of people don't understand what Beam stands for.
That's right. Yeah, it's actually a joke we tell that Beam stands for base editing and more, and we're always looking for what the And more is. And I think we've figured a lot of things out actually that fit into that bucket.
So Beam is a next-generation gene editing company. We work on CRISPR, but it's a new form of CRISPR. So we're using CRISPR
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
